Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Dec;43(12):6771-6782.
doi: 10.1007/s10072-022-06324-0. Epub 2022 Aug 25.

Efficacy of desferrioxamine mesylate in intracerebral hematoma: a systemic review and meta-analysis

Kai Zhao  1 , Jing Li  2 , Qiang Zhang  3 , Mingfei Yang  4
Affiliations
Meta-Analysis

Efficacy of desferrioxamine mesylate in intracerebral hematoma: a systemic review and meta-analysis

Kai Zhao et al. Neurol Sci. 2022 Dec.

Abstract

Background: Previous meta-analysis had concluded that desferrioxamine mesylate (DFO) could effectively treat intracerebral hematoma (ICH) in animal models. We hope to confirm that DFO could treat ICH patients effectively through the systemic review and meta-analysis of clinical researches.

Method: Data extraction included hematoma volume (HV), reduction of National Institute of Health Stroke Scale (NIHSS) scores, and relative perihematomal edema (RPHE). The standard mean difference (SMD) and 95% confidence interval (95%CI) were calculated by fixed effects model. I-square (I2) statistic was used to test the heterogeneity. All p values were two-side with a significant level at 0.05.

Results: Five randomized controlled trials were included in the meta-analysis, which included 239 patients. At 7 days after onset, there was significant difference of RPHE development (- 1.87 (- 2.22, - 1.51) (I2 = 0, p = 0.639)) and significant difference of HV absorption (- 0.71 (- 1.06, 0.36) (I2 = 17.5%, p = 0.271)) between DFO and control groups. There was significant difference of reduction of NHISS scores (0.25 (0.05, 0.46) (I2 = 0, p = 0.992)) between DFO and control groups at 30 days after onset.

Conclusion: DFO reduced HV and perihematomal edema in ICH patients at 7 days after onset and improve neurological function at 30 days after onset efficiently and safely. DFO might be a new route of improving treatment of ICH.

Keywords: Desferrioxamine mesylate; Intracerebral hematoma; Meta-analysis; Perihematomal edema; Treatment.

PubMed Disclaimer

Conflict of interest statement

The authors had no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This included employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Figures

Fig. 1
Fig. 1
Flowchart of article screening
Fig. 2
Fig. 2
Assessment of article quality
Fig. 3
Fig. 3
Forest plots for the comparisons of NHISS scores/HV/RPHE between DFO and control groups. NIHSS: National Institute of Health Stroke Scale. HV: hematoma volume. RPHE: relative perihematomal edema. DFO: desferrioxamine mesylate. SMD: standard mean difference. 95%CI: 95% confidence interval. p: p-value
Fig. 4
Fig. 4
Funnel plots of risk of publication bias of NHISS scores/HV/RPHE. NIHSS: National Institute of Health Stroke Scale. HV: hematoma volume. RPHE: relative perihematomal edema. SMD: standard mean difference
Fig. 5
Fig. 5
Subgroup analysis of NHISS scores referring to different dose of DFO. NIHSS: National Institute of Health Stroke Scale. DFO: desferrioxamine mesylate. SMD: standard mean difference. 95%CI: 95% confidence interval. p: p-value
Fig. 6
Fig. 6
Subgroup analysis of NHISS scores referring to different routes of administration of DFO. NIHSS: National Institute of Health Stroke Scale. DFO: desferrioxamine mesylate. SMD: standard mean difference. 95%CI: 95% confidence interval. p: p-value
Fig. 7
Fig. 7
Subgroup analysis of HV referring to different time of treatment. HV: hematoma volume. SMD: standard mean difference. 95%CI: 95% confidence interval. p: p-value
Fig. 8
Fig. 8
Subgroup analysis of HV referring to different routes of administration of DFO. HV: hematoma volume. DFO: desferrioxamine mesylate. SMD: standard mean difference. 95%CI: 95% confidence interval. p: p-value
Fig. 9
Fig. 9
Subgroup analysis of RPHE referring to different time of treatment. RPHE: relative perihematomal edema. SMD: standard mean difference. 95%CI: 95% confidence interval. p: p-value
Fig. 10
Fig. 10
Subgroup analysis of RPHE referring to different routes of administration of DFO. RPHE: relative perihematomal edema. DFO: desferrioxamine mesylate. SMD: standard mean difference. 95%CI: 95% confidence interval. p: p-value
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ziai WC, Carhuapoma JR. Intracerebral hemorrhage. Continuum (Minneap Minn) 2018;24(6):1603–1622. - PubMed
    1. Xia X, Ren Q, Cui J, et al. Radiomics for predicting revised hematoma expansion with the inclusion of intraventricular hemorrhage growth in patients with supratentorial spontaneous intraparenchymal hematomas. Ann Transl Med. 2022;10(1):8. doi: 10.21037/atm-21-6158. - DOI - PMC - PubMed
    1. Zhang Y, Khan S, Liu Y, et al. Modes of brain cell death following intracerebral hemorrhage. Front Cell Neurosci. 2022;16:799753. doi: 10.3389/fncel.2022.799753. - DOI - PMC - PubMed
    1. Codd R, Richardson-Sanchez T, Telfer TJ, et al. Advances in the chemical biology of desferrioxamine B. ACS Chem Biol. 2018;13(1):11–25. doi: 10.1021/acschembio.7b00851. - DOI - PubMed
    1. Armstrong A, Mandala A, Malhotra M, et al. Canonical Wnt signaling in the pathology of iron overload-induced oxidative stress and age-related diseases. Oxid Med Cell Longev. 2022;2022:7163326. doi: 10.1155/2022/7163326. - DOI - PMC - PubMed

LinkOut - more resources